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Background
The cyclic guanosine-3’,5’-monophosphate (cGMP)/
cGMP-dependent protein kinase type I (cGKI) pathway is
a potent negative regulator of platelet adhesion and aggre-
gation [1]; however, the role of cGMP/cGKI for platelet
biogenesis in vivo is unclear.
Results
Here we report thrombocytosis in conventional cGKI
null mutants (cGKIL1/L1) and gene-targeted cGKIa/b
rescue mice (referred to as cGKI-SM) with cGKI expres-
sion specifically restored in smooth muscle (SM), but
not in other cell types [2-4]. In contrast, conditional
knockouts lacking the cGKI protein specifically in the
megakaryocyte (MK)/platelet lineage (Pf4-Cretg/+;
cGKIL2/L2) did not display a related thrombocytosis phe-
notype, indicating that the high platelet count of
cGKIL1/L1 and cGKI-SM mutants is rather a reactive
response than an intrinsic defect in megakaryopoiesis. In
line with these findings, wild-type (WT) mice engrafted
with cGKI-deficient bone-marrow (BM) cells showed full
reconstitution of haematopoiesis and normal platelet
counts upon myeloablative radiotherapy. Stimulation of
BM-derived WT MKs using serum preparations from
cGKI-SM mutants strongly accelerated megakaryopoiesis,
suggesting that their high platelet counts develop in
response to soluble factors. Indeed, we confirm elevated
Interleukin-6 (IL-6) serum levels [5,6], a known cause for
reactive thrombocytosis, in cGKI-SM mutants, whereas
IL-6 was unaltered in Pf4-Cretg/+; cGKIL2/L2 mice and
cGKI-deficient BM chimaeras. Vice versa, antibody-
mediated blockage of IL-6 reduced platelet counts in
cGKI-SM mice, but not in WT mice.
Conclusion
We conclude that abnormal signalling of cGMP/cGKI in
non-hematopoietic cells affects thrombopoiesis via IL-6
resulting in a reactive thrombocytosis in vivo.
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